Related Experiment Video
Updated: Jul 31, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with
M A Abrera-Abeleda1, C Nishimura, J L H Smith
1Department of Otolaryngology, Division of Nephrology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Insights
Genetic variations in complement factor H (CFH) and CFHR5 are linked to membranoproliferative glomerulonephritis type II (MPGN II/DDD). Further studies are needed to confirm if these CFH and CFHR5 allele variants directly cause MPGN II/DDD.
Area of Science:
- Nephrology
- Genetics
- Immunology
Background:
- Membranoproliferative glomerulonephritis type II (MPGN II/DDD) leads to chronic kidney disease and end-stage renal disease.
- Deficiencies and mutations in the complement factor H (CFH) gene are linked to MPGN II/DDD, suggesting complement dysregulation in its development.
Purpose of the Study:
- To investigate if specific allele variants of CFH and CFHR5 are preferentially associated with the MPGN II/DDD disease phenotype.
- To explore the role of complement system dysregulation in MPGN II/DDD pathogenesis.
Main Methods:
- Genotyping of CFH and CFHR5 single nucleotide polymorphisms (SNPs) in MPGN II/DDD patients.
- Comparison of allele frequencies between 131 MPGN II/DDD patients and a control group without age-related macular degeneration.
Main Results:
- Significant differences in allele frequencies were observed for four SNPs in CFH and three SNPs in CFHR5 between MPGN II/DDD patients and controls.
- Specific allele variants of CFH and CFHR5 were identified as potentially associated with the MPGN II/DDD phenotype.
Conclusions:
- The study identified specific allele variants of CFH and CFHR5 associated with MPGN II/DDD.
- While these findings suggest a role for complement in MPGN II/DDD pathogenesis, functional studies are necessary to confirm the causal relationship.
- The identified associations may or may not be directly related to the disease's pathophysiology.
Introduction:
Membranoproliferative glomerulonephritis type II or dense deposit disease (MPGN II/DDD) causes chronic renal dysfunction that progresses to end stage renal disease in about half of patients within 10 years of diagnosis. Deficiency of and mutations in the complement factor H (CFH) gene are associated with the development of MPGN II/DDD, suggesting that dysregulation of the alternative pathway of the complement cascade is important in disease pathophysiology.
Subjects:
Patients with MPGN II/DDD were studied to determine whether specific allele variants of CFH and CFHR5 segregate preferentially with the MPGN II/DDD disease phenotype. The control group was compromised of 131 people in whom age related macular degeneration had been excluded.
Results:
Allele frequencies of four single nucleotide polymorphisms in CFH and three in CFHR5 were significantly different between MPGN II/DDD patients and controls.
Conclusion:
We have identified specific allele variants of CFH and CFHR5 associated with the MPGN II/DDD disease phenotype. While our data can be interpreted to further implicate complement in the pathogenesis of MPGN II/DDD, these associations could also be unrelated to disease pathophysiology. Functional studies are required to resolve this question.
More Related Videos
Related Concept Videos
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Nephrons
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Nephrotic Syndrome I : Introduction

